04-08-2011

Actelion announced that Joseph C. Scodari - for personal reasons - has resigned from Actelion's Board of Directors at the beginning of August 2011.Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented: "We would like to thank Joe for his dedication to Actelion. We have ...

more

Ponesimod to proceed to Phase III final stage of clinical development

03-08-2011

Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study ...

more

Otto Schwarz appointed Chief Operating Officer

09-06-2011

Actelion Ltd announced that Otto Schwarz has been appointed Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of Business Strategy & Operations. In addition to Commercial Operations and Business Strategy he assumes responsibility for Corporate Services, Global ...

more

25-05-2011

Actelion Ltd announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (pThe study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult ...

more

06-04-2011

Actelion Ltd announced the nomination of Jean-Pierre Garnier and Robert Bertolini for election to the Company's Board of Directors at the 2011 Annual General Meeting (AGM) of shareholders, to be held on 05 May 2011. When elected, Jean-Pierre Garnier will become a Vice Chairman together with ...

more

04-04-2011

Actelion Ltd announced that the company will receive this year's Prix Hermès de l'Innovation in the category "amélioration de la condition humaine" (improvement in the conditions of human life).The European Institute for Creative Strategies and Innovation awards the Prix Hermès annually to ...

more

31-01-2011

Actelion Ltd and GlaxoSmithKline announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the ...

more

05-01-2011

Actelion Ltd announced that Dr. Elias Zerhouni has resigned from Actelion's Board of Director at the end of 2010. Dr. Zerhouni will focus on his new role as President, Global Research and Development at Sanofi-aventis, an executive function he is assuming as of the beginning of 2011. Robert ...

more

14-12-2010

Actelion Ltd announced the official opening of its new Business Center in a ceremony attended by Federal President Doris Leuthard and other representatives from politics, business and science. Dr. Jean-Paul Clozel, Chief Executive Officer of Actelion said: "After a three-year construction ...

more

28-09-2010

Actelion Ltd announced the initial results of CONSCIOUS-2 a clinical study evaluating the safety and efficacy of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in clipped patients following aneurysmal subarachnoid hemorrhage (aSAH). The primary endpoint showed a ...

more